192 related articles for article (PubMed ID: 9842520)
1. [Quantitative changes in the immunoglobulin G subclass system--a reliable tumor marker in squamous epithelial carcinoma in the area of the head-neck].
Anderhuber W; Steinschifter W; Gotschuli A; Schauenstein E; Schauenstein K
Laryngorhinootologie; 1998 Oct; 77(10):564-8. PubMed ID: 9842520
[TBL] [Abstract][Full Text] [Related]
2. The IgG1/G2 subclass shift--a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck.
Anderhuber W; Steinschifter W; Schauenstein E; Gotschuli A; Habermann W; Fischer M; Felsner P; Schauenstein K
Br J Cancer; 1999 Apr; 79(11-12):1777-81. PubMed ID: 10206292
[TBL] [Abstract][Full Text] [Related]
3. Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
Schauenstein E; Lahousen M; Weblacher M; Steinschifter W; Estelberger W; Schauenstein K
Cancer; 1996 Aug; 78(3):511-6. PubMed ID: 8697398
[TBL] [Abstract][Full Text] [Related]
4. Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue.
Schauenstein E; Rabl H; Steinschifter W; Hirschmann C; Estelberger W; Schauenstein K
Cancer; 1997 Apr; 79(8):1482-6. PubMed ID: 9118027
[TBL] [Abstract][Full Text] [Related]
5. [The SCC antigen is not a reliable tumor marker in the ENT area. Value of squamous cell carcinoma antigen in diagnosis and follow-up of squamous epithelial carcinoma in the head-neck area. Results of a retrospective study over 6 years].
Gotschuli A; Anderhuber W; Danninger R; Habermann W
Laryngorhinootologie; 1998 Mar; 77(3):165-7. PubMed ID: 9577824
[TBL] [Abstract][Full Text] [Related]
6. [Detection of serum soluble fragments of cytokeratins 8 and 18 in patients with squamous epithelial carcinomas of the upper aerodigestive tract].
Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
Laryngorhinootologie; 1997 Sep; 76(9):554-8. PubMed ID: 9417185
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis of recurrences of head and neck carcinoma with the tumor marker SSC-antigen].
Arlt A; Luckhaupt H; Hildmann H
Laryngorhinootologie; 2000 Apr; 79(4):207-12. PubMed ID: 10838684
[TBL] [Abstract][Full Text] [Related]
8. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
9. [Second carcinomas in cancers of the mouth cavity, pharynx and larynx. Clinical, histopathologic and cell kinetic findings].
Esser D; Anke S; Roessner A; Freigang B
Laryngorhinootologie; 2000 Aug; 79(8):478-82. PubMed ID: 11006912
[TBL] [Abstract][Full Text] [Related]
10. [Serum soluble interleukin 2 receptor in patients with squamous epithelial carcinomas of the upper aerodigestive tract].
Gottschlich S; Werner JA; Lippert BM; Görögh T; Maune S; Rudert H
Laryngorhinootologie; 1995 Aug; 74(8):508-11. PubMed ID: 7575904
[TBL] [Abstract][Full Text] [Related]
11. [Relevance of colour-duplex echography for detection and therapy of recurrences in the follow-up of head and neck cancer].
Di Martino E; Hausmann R; Krombach GA; Nowak B; Tietze L; Gagel B; Zimny M; Westhofen M
Laryngorhinootologie; 2002 Dec; 81(12):866-74. PubMed ID: 12486624
[TBL] [Abstract][Full Text] [Related]
12. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
13. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
Spector JG; Sessions DG; Haughey BH; Chao KS; Simpson J; El Mofty S; Perez CA
Laryngoscope; 2001 Jun; 111(6):1079-87. PubMed ID: 11404625
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
15. [Squamous cell carcinoma antigen. Current clinical value of a new tumor marker in head and neck cancer; preliminary results of a prospective study after 12 months].
Clasen B; Roettger D; Senekowitsch R; Menz E
Laryngol Rhinol Otol (Stuttg); 1988 Aug; 67(8):420-5. PubMed ID: 3210877
[TBL] [Abstract][Full Text] [Related]
16. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
[TBL] [Abstract][Full Text] [Related]
17. [N-acetylneuraminic acid (sialic acid) as a tumor marker in head and neck cancers].
Fischer F; Egg G
HNO; 1990 Oct; 38(10):361-3. PubMed ID: 2283329
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
19. [The expression of zeta-chain of the T cell receptor as prognostic marker for patients with head and neck cancer].
Müller D; Lang S; Roskrow M; Wollenberg B
Laryngorhinootologie; 2002 Jul; 81(7):516-20. PubMed ID: 12173063
[TBL] [Abstract][Full Text] [Related]
20. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
